Status: Recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.
Participants needed: 51
Trial details
Phase: Phase 2Age: 7-9Biological sex: MaleType: InterventionalSponsor: Satellos Bioscience, Inc.Updated: Aug 14, 2026Locations: 21
Eligibility criteria
Has a definitive diagnosis of DMD based on documented clinical findings and prio... [+8]
Ambulatory patients expected to experience loss of ambulation within ≤ 12 months... [+7]